Search Results
Jul 14, 2026, 10:00 ET ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease
monoclonal antibody. It is an Fc-modified antibody designed based on its mechanism of action in neurodegenerative diseases, where the therapeutic benefit is Cmax-dependent rather than driven by continuous exposure. Its short half-life, together with intermittent administration, is intended to minimize exposure
More news about: ImmunoBrain Checkpoint Inc.
Jun 14, 2026, 20:15 ET CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
Tmax of 10 days. At the highest dose level (6.0×10⁸ cells), the median Cmax (reaching 10⁵) and AUC0-t (reaching 6×10⁵) of CT1190B far exceeded those of currently approved autologous CAR‑T products (Cmax: 10³–10⁴; AUC 0-t: 10⁴–2×10⁵).About CT0596CT0596
More news about: CARsgen Therapeutics
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
pharmacokinetics properties support once-daily oral administration: After a single oral dose, IBI3032's systemic exposure (AUCinf and Cmax) increased in an approximately dose-proportional manner across 0.3–6 mg dose range; peak plasma concentration (Tmax) occurred 5–12 hours
More news about: Innovent Biologics
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
peak levels and was eliminated rapidly, ABO2203 exhibited a delayed peak TCE concentration and prolonged half-life. The lower peak concentration (Cmax) may help mitigate cytokine release, while sustained mRNA expression may contribute to more durable anti-tumor efficacy than P4107.Encouraging
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
peak levels and was eliminated rapidly, ABO2203 exhibited a delayed peak TCE concentration and prolonged half-life. The lower peak concentration (Cmax) may help mitigate cytokine release, while sustained mRNA expression may contribute to more durable anti-tumor efficacy than P4107.Encouraging
More news about: Abogen
Mar 24, 2026, 08:13 ET Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
(0%)No dose-limiting toxicities observed.No treatment discontinuations due to adverse eventsDay 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful ResponseNEW
More news about: Hoth Therapeutics, Inc.
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
concentration (Tmax) ranged from 4.05 to 14.1 days, and the mean half-life (T1/2) ranged from 55.0 to 65.8 days. HBM9378 exposure (Cmax and AUC) increased in an approximately dose-proportional manner across the dose range of 20 to 900 mg. The incidence of anti-drug antibody (ADA)
More news about: Harbour BioMed
Mar 19, 2026, 09:00 ET ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026
monoclonal antibody. It is an Fc-modified antibody designed based on its mechanism of action in neurodegenerative diseases, where the therapeutic benefit is Cmax-dependent rather than driven by continuous exposure. Its short-lived profile, together with intermittent administration, is intended to minimize exposure
More news about: ImmunoBrain Checkpoint Inc.
Feb 10, 2026, 09:10 ET Qnovia's Inhaled Nicotine Replacement Therapy Delivers Positive Results in First Human Study
nicotine uptake, an essential factor for effective craving control and smoking cessation. Reaching peak blood levels in 7 minutes with just 10 puffs (Cmax 8.7 ng/mL), demonstrating a Tmax comparable to combustible cigarettes of ~6 minutes, significantly outperforming authorized legacy nicotine replacement
More news about: Qnovia, Inc.
Jan 20, 2026, 04:00 ET Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
potent than retatrutide for GLP-1R, GIPR and GCGR, respectively. ASC37 is engineered for a longer observed half-life (as measured by time to 50% Cmax), compared to once-weekly administered retatrutide, to support once-monthly subcutaneous (SQ) dosing, with injection volume of one milliliter or
More news about: Ascletis Pharma Inc.
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
experience and rapid administration (minutes vs hours). In addition, subcutaneous dosing may provide an optimized pharmacokinetic profile with lower Cmax and more stable exposure, which may support improved safety and efficacy.BHV-1530 (FGFR3 ADC): Biohaven also provides an update of the ongoing
More news about: Biohaven Ltd.
Jan 09, 2026, 02:31 ET No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321
to date. These observations are based on data available to date, and the study is ongoing.Mean Cmax values in plasma from Cohorts 1 and 2 indicate very low systemic exposure to diclofenac. Cmax data from Cohorts 3 and 4 are pending. Plasma concentrations of diclofenac-derived by-products have been
More news about: Synartro AB
Jan 09, 2026, 02:29 ET No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321
to date. These observations are based on data available to date, and the study is ongoing.Mean Cmax values in plasma from Cohorts 1 and 2 indicate very low systemic exposure to diclofenac. Cmax data from Cohorts 3 and 4 are pending. Plasma concentrations of diclofenac-derived by-products have been
More news about: Synartro AB
Nov 19, 2025, 07:00 ET Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
treatment for moderate-to-severe AD. Safety results showed low systemic exposure following topical administration, with mean Cmax values of 0.06 ng/mL and 0.15 ng/mL for the 0.3% and 1.0% groups respectively, hundreds of times lower than the human whole-blood IC50. LNK01004 demonstrated
More news about: Lynk Pharmaceuticals Co., Ltd.
Nov 10, 2025, 02:44 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 achieved a similar maximum plasma concentration (Cmax) at a four times higher monthly dose compared to weekly semaglutide. Additionally, CAM2056 showed longer time to Cmax and an extended-release profile suitable for monthly dosing. CAM2056
More news about: Camurus AB
Nov 10, 2025, 02:41 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 achieved a similar maximum plasma concentration (Cmax) at a four times higher monthly dose compared to weekly semaglutide. Additionally, CAM2056 showed longer time to Cmax and an extended-release profile suitable for monthly dosing. CAM2056
More news about: Camurus AB
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
to reduce to fifty percent (50%) of ASC30's Cmax) reached 46 days and 75 days, for ASC30 subcutaneous (SQ) treatment formulation (Injection A) and ASC30 SQ maintenance formulation (Injection B), respectively. Cmax-to-Cday29 ratio of 1.5:1, supports ASC30 SQ treatment
More news about: Ascletis Pharma Inc.
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
reached the timepoint for efficacy assessment. A total of 6 patients received the full lymphodepletion and recommended cell dose, with a median Cmax reaching levels on the order of 10⁵ copies/ug gDNA. The primary safety signals of CT1190B were CRS,
More news about: CARsgen Therapeutics
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. ASC36 is engineered for a longer observed half-life (as measured by time to 50% Cmax) and higher bioavailability per milligram of peptide to support once-monthly subcutaneous (SQ) dosing, with injection volume of one milliliter
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life (as measured by time to 50% Cmax) in participants with obesity in the Phase Ib study (
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
including tocilizumab, corticosteroids, autologous stem cell infusion, and anti-infective therapy. CAR-T cells expanded robustly, with a peak copy number (Cmax) of 161,971 copies/μg gDNA, and copy numbers remained at 10³ by Week 8. Efficacy assessments at both Week 4 and Week 8 post-infusion showed stringent
More news about: CARsgen Therapeutics
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
potent than tirzepatide for both GLP-1R and GIPR in vitro. ASC35 is engineered for a longer observed half-life (as measured by time to 50% Cmax) and higher bioavailability per milligram of peptide, compared to once-weekly administered tirzepatide, to support once-monthly SQ dosing, with
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
8.000 (3.00-24.00) Cmax (ng/mL) 272±101
More news about: Ascletis Pharma Inc.